3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
8
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Urinary Bladder Neoplasms
5
Leukemia, Myeloid, Acute
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Lung Neoplasms
4
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Mouth Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Ureteral Neoplasms
2
Stomatitis
2
Recurrence
2
Oropharyngeal Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
COVID-19
2
Brain Neoplasms
2
Adenocarcinoma
2
Interventions
antineoplaston AS 2-1
4
antineoplaston A10
4
Cyclophosphamide
4
Cisplatin
4
Temozolomide
3
Radiotherapy
3
dactolisib
2
Vincristine
2
Filgrastim
2
Everolimus
2
Etoposide
2
Bevacizumab
2
spartalizumab
1
sargramostim
1
pasireotide
1
ganitumab
1
gallium Ga 68 dotatate
1
fosbretabulin
1
cixutumumab
1
belzutifan
1
aldesleukin
1
Topotecan
1
Thiotepa
1
TH 302
1
Sunitinib
1
Standard of Care
1
Pregabalin
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroectodermal Tumors, Primitive
×
Standard of Care
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled